Related Experiment Video
Updated: May 8, 2026
A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
A novel HDAC1-specific inhibitor prevents estrogen deficiency-induced osteoporosis in mice by inhibiting osteoclast
Hang Yuan1, Yizhong Bao2, Li Li3
1Affiliated Zhejiang Hospital, School of Medicine, Zhejiang University, Hangzhou 310013, China; Department of Orthopedics Surgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China.
Abstract:
Postmenopausal osteoporosis (PMOP) features reduced bone mass and deteriorated bone microstructure, increasing fracture risk. Estrogen deficiency-induced osteoclast overactivation is a primary driver. OCP-001, a novel highly selective HDAC1 inhibitor, was investigated. TRAP staining showed dose-dependent inhibition of osteoclast differentiation by OCP-001. qPCR revealed concomitant downregulation of RANKL-induced osteoclast marker genes (Trap, DC-Stamp, NFATc1, ATP60) and key regulatory proteins (c-Fos, NFATc1, Blimp-1, IRF-8). In an ovariectomized (OVX)-induced PMOP mouse model, body weight monitoring showed no toxicity from OCP-001 treatment. Micro-CT analysis confirmed that it effectively prevented femoral bone mass loss and microstructural deterioration. Histological analysis further verified its inhibition of OVX-induced osteoclastogenesis. Furthermore, OCP-001 normalized OVX-altered serum bone turnover markers (PINP, β-CTx). Mechanistically, OCP-001 suppressed osteoclast differentiation partly via inhibiting the Blimp-1/IRF-8 pathway. Thus, the selective HDAC1 inhibitor OCP-001 alleviates OVX-induced bone loss and deterioration by potently inhibiting osteoclastogenesis and function, supporting its potential as a PMOP therapeutic.
Insights
OCP-001, a selective HDAC1 inhibitor, effectively treats postmenopausal osteoporosis by inhibiting osteoclast overactivation and bone loss in mice. This novel therapeutic candidate shows promise for preventing fractures associated with estrogen deficiency.
Area of Science:
- Biomedical research
- Pharmacology
- Bone biology
Background:
- Postmenopausal osteoporosis (PMOP) is characterized by reduced bone mass and microstructural deterioration, leading to increased fracture risk.
- Estrogen deficiency is a primary driver of PMOP, causing osteoclast overactivation.
- There is a need for novel therapeutic agents to combat PMOP.
Purpose of the Study:
- To investigate the efficacy and mechanism of OCP-001, a novel selective HDAC1 inhibitor, in treating PMOP.
- To evaluate OCP-001's effect on osteoclast differentiation and function.
- To assess OCP-001's impact on bone mass and microstructure in an ovariectomized (OVX) mouse model.
Main Methods:
- TRAP staining and qPCR were used to assess osteoclast differentiation and gene expression.
- An OVX-induced PMOP mouse model was employed to evaluate OCP-001's in vivo effects.
- Micro-CT and histological analyses were performed to assess bone mass and microstructure.
- Serum bone turnover markers (PINP, β-CTx) were measured.
Main Results:
- OCP-001 demonstrated dose-dependent inhibition of osteoclast differentiation and downregulated key osteoclast marker genes.
- In OVX mice, OCP-001 prevented bone mass loss and microstructural deterioration without toxicity.
- OCP-001 normalized OVX-altered serum bone turnover markers.
- Mechanistically, OCP-001 suppressed osteoclast differentiation via the Blimp-1/IRF-8 pathway.
Conclusions:
- OCP-001 effectively alleviates OVX-induced bone loss and deterioration by inhibiting osteoclastogenesis and function.
- The selective HDAC1 inhibitor OCP-001 shows significant potential as a therapeutic agent for postmenopausal osteoporosis.
Related Concept Videos
02:34Inhibition of Cdk Activity
02:34Inhibition of CDK Activity